Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer
30 October 2020 - 11:17PM
Business Wire
New branding will support upcoming combination
clinical trials, including the Company’s trial combining REQORSA™
immunogene therapy drug with AstraZeneca’s Tagrisso®, which
received FDA Fast Track Designation earlier in 2020
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a
clinical-stage gene therapy company focused on developing
life-changing therapies for patients with cancer and diabetes,
today announced the launch of new branding for its upcoming
oncology clinical trials combining its lead drug candidate,
REQORSA™ (quaratusugene ozeplasmid), with AstraZeneca’s Tagrisso®
(osimertinib), which received U.S. Food and Drug Administration
(FDA) Fast Track Designation earlier this year, and for the
combination of REQORSA with Merck’s Keytruda® (pembrolizumab), for
the treatment of non-small cell lung cancer (NSCLC).
These trials will use the trial brand “Acclaim,” which the
Company believes evokes its enthusiasm and the hope these trials
represent for NSCLC patients and the oncology community. Acclaim-1
will be used to identify the REQORSA and Tagrisso combination
clinical trial, and Acclaim-2 will be used to identify the REQORSA
and Keytruda combination clinical trial.
“We are enthusiastically preparing for our upcoming clinical
trials and are excited to launch the adoption of this branding,”
said Rodney Varner, President and Chief Executive Officer of
Genprex. “We believe the Acclaim brand communicates our passion for
providing hope to NSCLC patients for important new treatment
options in the fight against this devastating disease and aligns us
with the clinical, medical and patient communities.”
The trial brand was developed in order to encourage early
exposure of the Company’s clinical programs to the broad audience
that Genprex’s business addresses, including patients, healthcare
practitioners, clinical investigators, investors, employees and
others. Genprex plans to initiate the Acclaim-1 clinical trial and
the Acclaim 2 clinical trial in the first-half of 2021. Acclaim-1
is a Phase 1/2 clinical trial using a combination of REQORSA with
Tagrisso in patients with late stage NSCLC with mutated epidermal
growth factor receptors (“EGFRs”) whose disease progressed after
treatment with Tagrisso. Acclaim-2 is a Phase 1/2 clinical trial
using a combination of REQORSA with Keytruda in NSCLC patients who
are low expressors (1 to 49%) of the protein, programmed
death-ligand 1 (PD-L1).
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused
on developing potentially life-changing therapies for patients with
cancer and diabetes. Genprex’s technologies are designed to
administer disease-fighting genes to provide new therapies for
large patient populations with cancer and diabetes who currently
have limited treatment options. Genprex works with world-class
institutions and collaborators to develop drug candidates to
further its pipeline of gene therapies in order to provide novel
treatment approaches. The Company’s lead product candidate,
REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a
treatment for non-small cell lung cancer (NSCLC). REQORSA has a
multimodal mechanism of action that has been shown to interrupt
cell signaling pathways that cause replication and proliferation of
cancer cells; re-establish pathways for apoptosis, or programmed
cell death, in cancer cells; and modulate the immune response
against cancer cells. REQORSA has also been shown to block
mechanisms that create drug resistance. In January 2020, the U.S.
Food and Drug Administration granted Fast Track Designation for
REQORSA for NSCLC in combination therapy with osimertinib
(AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose
tumors progressed after treatment with osimertinib alone. For more
information, please visit the Company’s web site at www.genprex.com
or follow Genprex on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes, regarding
potential, current and planned clinical trials, regarding the
Company’s future growth and financial status and regarding our
commercial partnerships and intellectual property licenses. Risks
that contribute to the uncertain nature of the forward-looking
statements include the presence and level of the effect of our
product candidates, alone and in combination with other therapies,
on cancer; the timing and success of our clinical trials and
planned clinical trials of REQORSA™ immunogene therapy drug, alone
and in combination with targeted therapies and/or immunotherapies,
and whether our other potential product candidates, including
GPX-002, our gene therapy in diabetes, advance into clinical
trials; the success of our strategic partnerships, including those
relating to manufacturing of our product candidates; the timing and
success at all of obtaining FDA approval of REQORSA and our other
potential product candidates including whether we receive or
benefit from fast track or similar regulatory designations; costs
associated with developing our product candidates, whether we
identify and succeed in acquiring other technologies and whether
patents will ever be issued under patent applications that are the
subject of our license agreements or otherwise. These and other
risks and uncertainties are described more fully under the caption
“Risk Factors” and elsewhere in our filings and reports with the
United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201030005169/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2024 to May 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From May 2023 to May 2024